CAS NO: | 1799328-86-1 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | ASTX660 is an orally bioavailable dual antagonist of cellular inhibitor ofapoptosisprotein (cIAP) andX-linked inhibitor of apoptosisprotein (XIAP). | ||||||||||||||||
IC50& Target | cIAP, XIAP[1] | ||||||||||||||||
体外研究 (In Vitro) | ASTX660 is an orally bioavailable dual antagonist of cIAP and XIAP, currently being investigated in a single-agent Phase 1/2 clinical trial in patients with advanced solid tumors and lymphomas. Twenty-one triple-negative breast cancer (TNBC) cell lines are treated with ASTX660in vitroand it is found that 43% are sensitive to ASTX660[1]. | ||||||||||||||||
体内研究 (In Vivo) | In HCC1806 xenografts in mice, ASTX660 (daily oral treatment) causes moderate tumor growth inhibition but not regression[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 539.68 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C30H42FN5O3 | ||||||||||||||||
CAS 号 | 1799328-86-1 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 100 mg/mL(185.29 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|